Clinical Outcome of the Chromosomal Abnormalities in Acute Myeloid Leukemia with M2 Subtype / 대한혈액학회지
Korean Journal of Hematology
;
: 181-188, 2001.
Article
in Korean
| WPRIM
| ID: wpr-720534
ABSTRACT
BACKGROUND:
Acute myelod leukemia (AML) is a hematologic malignant disease characterized by uncontrolled proliferation of myeloid cells in marrow and arrest in their maturation. It accounts for 70~80% of chromosomal abnormalities and t (8;21) has been found in 40% of AML-M2. Because cytogenetic studies can help classifying the disease, providing the clues of disease progression and monitoring remission after chemotherapy, we have performed cytogenetic studies to identify the incidence of t (8;21) and other chromosomal abnormalities and to assure their prognostic significance in patients with AML-M2.METHODS:
From August 1998 to July 2000, 38 patients with AML-M2 were treated with ara-C and idarubicin in order to induce complete remission. We evaluated chromosomal abnormalities by high resolution banding technique. We divided patients into 3 groups. Patients having normal and intermediate risk karyotype belonged to group A, t (8;21) to group B and, unfavorable and undetermined prognostic karyotype to group C.RESULTS:
The incidence of chromosomal abnormalities was 71% (27/38), and the proportion of A, B, and C group were 40%, 30% and 30%, respectively. The median follow up duration of evaluable patients was 381 (55~1,295) days. The complete remission (CR) rate accounted for 79% (30/38). The CR rate in A, B and C group were 88% (14/16), 91% (10/ 11) and 55% (6/11), respectively (P=0.06). The median remission duration had not been reached yet. The median remission duration of group A and B had not been reached yet, but that of group C was 337 days (P=0.60). The overall median survival duration was 567 days, and the median survival duration of group B had not been reached yet, otherwise those that of group A and C were 432 days and 364 days, respectively (P=0.02).CONCLUSION:
The incidence of chromosomal abnormalities was observed 71% in patients with AML-M2. The patients with t (8;21) showed higher complete remission rate and tendency to have longer remission duration and survival duration.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Bone Marrow
/
Idarubicin
/
Leukemia, Myeloid, Acute
/
Leukemia
/
Incidence
/
Follow-Up Studies
/
Chromosome Aberrations
/
Disease Progression
/
Myeloid Cells
/
Cytarabine
Type of study:
Incidence study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Hematology
Year:
2001
Type:
Article
Similar
MEDLINE
...
LILACS
LIS